Lyell Immunopharma, Inc. - Common Stock (NQ:LYEL)

20.06 -0.79 (-3.79%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2026 Add to My Watchlist

Price and Volume

Volume	52,199
Open	21.23
Bid (Size)	19.89 (100)
Ask (Size)	20.07 (200)
Prev. Close	20.85
Today's Range	19.54 - 21.23
52wk Range	7.650 - 45.00
Shares Outstanding	240,471,497
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026

May 06, 2026

From Lyell Immunopharma, Inc

Via GlobeNewswire

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference

April 07, 2026

From Lyell Immunopharma, Inc

Via GlobeNewswire

Performance

YTD	-30.8%	-30.8%
1 Month	-7.5%	-7.5%
3 Month	-17.0%	-17.0%
6 Month	+21.3%	+21.3%
1 Year	+141.3%	+141.3%

More News

Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

March 12, 2026

From Lyell Immunopharma, Inc

Via GlobeNewswire

Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer

March 09, 2026

From Lyell Immunopharma, Inc

Via GlobeNewswire

Lyell Immunopharma Announces Participation in March Investor Conferences

February 23, 2026

From Lyell Immunopharma, Inc

Via GlobeNewswire

The market is filled with gapping stocks in Wednesday's session. ↗

February 18, 2026

Via Chartmill

Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma

February 12, 2026

From Lyell Immunopharma, Inc

Via GlobeNewswire

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

December 24, 2025

From Equity Insider

Via GlobeNewswire

Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗

December 08, 2025

Via The Motley Fool

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

December 07, 2025

From Lyell Immunopharma, Inc

Via GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

November 12, 2025

From Lyell Immunopharma, Inc

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 10, 2025

Via Benzinga

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

November 10, 2025

From Lyell Immunopharma, Inc

Via GlobeNewswire

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

November 03, 2025

From Lyell Immunopharma, Inc

Via GlobeNewswire

This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

September 26, 2025

Via Benzinga

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

September 03, 2025

From Lyell Immunopharma, Inc

Via GlobeNewswire

Lyell Immunopharma Announces Participation in September Investor Conferences

September 02, 2025

From Lyell Immunopharma, Inc

Via GlobeNewswire

Lyell Immunopharma Inc (NASDAQ:LYEL) Reports Q2 2025 Earnings Beat with Clinical Progress on LYL314 ↗

August 12, 2025

Via Chartmill

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

August 12, 2025

From Lyell Immunopharma, Inc

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 31, 2025

Via Benzinga

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

July 25, 2025

From Lyell Immunopharma, Inc

Via GlobeNewswire

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

June 24, 2025

Via Benzinga

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

June 23, 2025

From Lyell Immunopharma, Inc

Via GlobeNewswire

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

June 17, 2025

From Lyell Immunopharma, Inc

Via GlobeNewswire

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

June 09, 2025

From Lyell Immunopharma, Inc

Via GlobeNewswire

Frequently Asked Questions

Is Lyell Immunopharma, Inc. - Common Stock publicly traded?

Yes, Lyell Immunopharma, Inc. - Common Stock is publicly traded.

What exchange does Lyell Immunopharma, Inc. - Common Stock trade on?

Lyell Immunopharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Lyell Immunopharma, Inc. - Common Stock?

The ticker symbol for Lyell Immunopharma, Inc. - Common Stock is LYEL on the Nasdaq Stock Market

What is the current price of Lyell Immunopharma, Inc. - Common Stock?

The current price of Lyell Immunopharma, Inc. - Common Stock is 20.06

When was Lyell Immunopharma, Inc. - Common Stock last traded?

The last trade of Lyell Immunopharma, Inc. - Common Stock was at 05/07/26 04:00 PM ET

What is the market capitalization of Lyell Immunopharma, Inc. - Common Stock?

The market capitalization of Lyell Immunopharma, Inc. - Common Stock is 4.82B

How many shares of Lyell Immunopharma, Inc. - Common Stock are outstanding?

Lyell Immunopharma, Inc. - Common Stock has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.